Calcium channel blockers and Alzheimer’s disease*

Yi Tan, Yulin Deng, Hong Qing

School of Life Science, Beijing Institute of Technology, Beijing 100081, China

Abstract
Alzheimer’s disease is characterized by two pathological hallmarks: amyloid plaques and neurofibrillary tangles. In addition, calcium homeostasis is disrupted in the course of human aging. Recent research shows that dense plaques can cause functional alteration of calcium signals in mice with Alzheimer’s disease. Calcium channel blockers are effective therapeutics for treating Alzheimer’s disease. This review provides an overview of the current research of calcium channel blockers involved in Alzheimer’s disease therapy.

Key Words: Alzheimer’s disease; calcium channel; calcium homeostasis; Alzheimer’s disease pathogenesis; β-amyloid; calcium channel blocker

INTRODUCTION
Calcium plays an important role in many aspects of normal neuronal physiology, including synaptic plasticity and learning[1]. Though disturbances in calcium homeostasis have been observed in cells from Alzheimer’s disease (AD) patients for many years[2-3], little attention was paid to calcium channel blockers as therapeutic targets. There are multiple types of calcium channels in the membrane, beta-amyloid (Aβ)-formed calcium channels and calcium-related proteins[4-5]. This review provides an overview of the current research of calcium channel blockers involved in AD therapy.

OVERVIEW OF CALCIUM CHANNELS IN AD
Calcium homeostasis can be disrupted in human aging[6]. Calcium channels can be basically divided into voltage-gated calcium channels and glutamate receptors calcium channel, such as N-methyl-D-aspartate (NMDA) receptor channels and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA). Voltage gated calcium channels are subdivided into type L, type Q, type P, and type N, to name a few[7].

Calcium channel adjusts the concentration of calcium and contributes to physiological functions through gates in the phospholipid bilayer. Type N and Q voltage-gated calcium channels support neuronal synaptic transmission between the hippocampal CA1 and CA3 regions[8]. L-type calcium channels mainly exist in the cell body of central neurons and proximal dendrites, while P-type calcium channels exist in a specific area of Purkinje cells, and at the end of axons[9].

NMDA receptor channels include glutamate receptor channels and voltage-gated channels, and have high permeability for calcium. NMDA receptor channels are most dense in the cerebral cortex and the hippocampus[10].

POSTULATED MECHANISMS ASSOCIATED WITH CALCIUM DYSREGULATION AND AD PATHOGENESIS
Aβ, a secreted form of APP (sAPPα) and the amyloid precursor protein intracellular domain (AICD) are generated by sequential cleavages of the amyloid precursor protein by β and γ-secretases[11]. These processes likely happen in the endoplasmic reticulum (ER) and plasma membrane. The formation of calcium permeable channels enhances calcium influx into the cell. Phosphatidylserine in the plasma membrane surface facilitates the association of Aβ oligomers with the plasma membrane. While calcium-related mitochondrial impairment can happen, phosphatidylserine can be triggered flipping from the inner position to the surface of the cell membrane[12]. At the same time, Aβ interacts with Fe2+ and Cu2+ to generate reactive oxygen species. The formation of...
reactive oxygen species leads to lipid peroxidation which generates the neurotoxic aldehyde 4-hydroxynonenal. 4-hydroxynonenal can impair membrane transporters, guanosine triphosphate-binding proteins, and calcium channels through covalent modifications. In addition, Aβ causes oxidative stress and dysregulation of calcium, which impairs the electron transport chain, decreases production of adenosine triphosphate (ATP) and increases production of superoxide anion radicals. Then membrane depolarization is caused by the loss of membrane integrity and the reduction in ATP levels. These results lead to calcium influx through NMDA channels and voltage-gated calcium channels. Aβ oligomers also directly affect the activity of NMDA receptors and voltage-gated calcium channels. AICD translocates to the nucleus and interacts with transcription regulators in ways that perturb calcium homeostasis. Recent studies show that presenilins function as ER calcium leak channels. Furthermore, flavin adenine dinucleotide-associated mutations impair this Ca\(^{2+}\) leak-channel function which results in excessive accumulation of Ca\(^{2+}\) in the ER. Finally, calcium is released through ryanodine receptors and inositol 1, 4, 5-trisphosphate receptor channels (Figure 1). A previous study also showed that presenilins can interact directly or indirectly with inositol 1, 4, 5-trisphosphate receptors, ryanodine receptors, and smooth ER Ca\(^{2+}\)-ATPases to alter ER calcium release and uptake. Calcium homeostasis modulator 1, which is likely associated with a passive Ca\(^{2+}\) leak channel, is located mainly in the ER. The protein reelin enhances Ca\(^{2+}\) influx through NMDA receptor channels by binding to the apolipoprotein E receptor 2 which could block the actions of reelin. In addition, amyloidogenic APP processing might prevent α-secretase cleavage of APP and generate a secreted form of APPα. The sAPPα activates a cyclic guanosine monophosphate signaling pathway that activates K+ channels, which hyperpolarizes the membrane and reduces Ca\(^{2+}\) influx. Calcium influx through calcium homeostasis modulator 1 reduces Aβ generation and promotes the α-secretase pathway. The store-operated calcium channels localized in the plasma membrane allow Ca\(^{2+}\) refilling via capacitative calcium entry. Calcium levels become raised in the cytosol, which activates calcium-related proteins and facilitates long-term depression, inhibits long-term potentiation, modifies neuronal cytoskeleton, causes synaptic loss, oxidative damage, excitotoxicity, cellular apoptosis and necrosis, and increases Aβ production and tau hyperphosphorylation. Mitochondria absorb excessive calcium in the cytosol through mitochondrial Ca\(^{2+}\) uniporters.

Figure 1: Postulated mechanisms associated with calcium dysregulation and calcium channel blockers in Alzheimer’s disease. Beta-amyloid oligomers, which can insert in the plasma membrane, can form pores or interact with calcium channels to influence calcium influx or release from the endoplasmic reticulum (ER) or mitochondrial stores. Amyloid precursor protein intracellular domain (AICD) which can move to the nucleus interacts with Fe65 and Tip60 to modify gene transcription. Presenilins can function as ER calcium leak channels which can be repaired by flavin adenine dinucleotide (FAD)-associated mutants. FAD-associated mutant presenilins can also interact with inositol 1, 4, 5-trisphosphate receptors (IP3R), ryanodine receptors (RyR), and smooth ER Ca\(^{2+}\)-ATPases (SERCA) to influence calcium levels. The mechanisms describe potential targets for treating Alzheimer’s disease. Some drugs that target calcium channels, such as memantine and nimodipine, are efficacious for treating Alzheimer’s disease. The star represents potential targets for the future.
This leads to calcium overloading in the mitochondria which results in the opening of mitochondrial permeability-transition pores. This process damages the mitochondrial ultrastructure, inhibits mitochondrial ATP production and other energy-dependent functions, and releases calcium stored in the mitochondria. Thus, the neuronal calcium signaling is further deregulated. The accumulation of Aβ in the mitochondria and the direct interaction of Aβ with cyclophilin D also facilitates calcium-induced mitochondrial permeability transition pore opening.

**CALCIUM CHANNEL BLOCKERS AND RECENT RESEARCH IN AD THERAPY**

Because of their chemical structures, voltage-gated calcium channel blockers can be mainly divided into three parts: (1) dihydropyridines, such as nifedipine, nimodipine, nicardipine; (2) benzothiazepines, such as diltiazem; (3) phenylalkylamines, such as verapamil. Dihydropyridines are widely used to vasodilate arterial resistance vessels and to increase the reflex in the sympathetic response. The overall hemodynamic effect is a drop in blood pressure and an increase in cardiac output, heart rate, and contractility.

Targeting the glutamatergic system, specifically NMDA receptors, offers a novel treatment approach because of the limited efficacy of existing drugs targeting AD. Memantine has been used in AD therapy as a noncompetitive NMDA receptor antagonist with low affinity. Memantine increases the expression of the NMDA receptor subunit 2B and the postsynaptic density-95. Memantine also binds to NMDA receptors on brain cells to help reduce abnormal activity in the brain, and to block the activity of excessive glutamate. Memantine binds to NMDA receptors with a higher affinity than Mg ions to inhibit the prolonged influx of Ca ions, which leads to neuronal toxicity. Ketamine is a non-competitive NMDA receptor antagonist and likely impairs the memory function of the brain in AD.

AD cells produce Aβ which leads to cell death. Calcium channel blockers protect AD cells from Aβ oligomer production. Recent research also indicates that isradipine has a better therapeutic effect compared with verapamil, diltiazem, isradipine and nimodipine. All of these drugs are L-voltage-gated calcium channel blockers.

**OTHER CANDIDATES THAT BLOCK OR TARGET CALCIUM CHANNELS IN THE TREATMENT OF AD**

Juliflorine, a piperidinium alkaloid, is isolated from the leaves of *Prosopis juliflora*. Juliflorine is a non-competitive inhibitor of the enzymes, acetylcholinesterase and butryrylcholinesterase. Its potential calcium channel blocking activity and safety profile in the human neutrophil viability assay make juliflorine a leading candidate for the treatment of AD. Juliflorine can also be used as a scaffold to synthesize new derivatives.

The senescence-accelerated mouse (SAM) prone/8 (SAMP8) is a model for investigating the fundamental mechanisms of AD at the gene and protein levels, and the SAM resistant/1 (SAMR1) mouse is its normal control. Calcium/calmodulin-dependent protein kinase II-α is one of the most abundant subunits of calcium/calmodulin dependent protein kinase II in the cerebral cortex and hippocampus. A previous study has shown that the expression of mRNA and protein of calmodulin-dependent protein kinase II was significantly increased in the cerebral cortex and hippocampus of SAMP8 after 10 months of age, but was down-regulated when treated with some anti-AD drugs (for example, natural product huperzine A and some traditional Chinese medicinal prescriptions), suggesting that calmodulin-dependent protein kinase II may play an important role in age-related cognitive deterioration in AD, and may be a potential target for anti-AD drugs.

The ryanodine receptor plays a vital role in the regulation of calcium release from the ER in the brain, so the impairment of ryanodine receptors contributes to the pathogenesis of AD. Recent studies have revealed that alterations in ryanodine receptor binding and function are very early events in the pathogenesis of AD, and may be fundamental to the progression of both neurofibrillary and β-amyloid pathologies. Ryanodine receptors increase early in the disease, prior to the loss of ryanodine receptors that is correlated with the progression of neurofibrillary pathology and amyloid deposition. This means that ryanodine receptor-induced calcium release in the ER may be crucially involved in the formation of the pathological hallmarks of AD.

**CONCLUSION**

Ample evidence shows that calcium dysregulation plays an important role in AD. Although the precise pathogenesis of AD remains unclear, many calcium channel blockers have proved efficacious in numerous cell culture and animal models of AD. Furthermore, most of these treatments target receptor-operated calcium channels and voltage-gated calcium channels. There are still new potential targets on the horizon for the development of drugs directed towards calcium channels.

**Author contributions:** Yi Tan was responsible for manuscript writing. Yulin Deng and Hong Qing provided ideas for the manuscript.

**Conflicts of interest:** None declared.

**Funding:** This project was supported by the National Natural Science Foundation of China, No. 81171206.

**Acknowledgments:** We would like to thank all the members of Professor Qing’s team for critical revisions and many helpful discussions.
REFERENCES

[1] Emilsson L, Saete P, Jazin E. Alzheimer's disease: mRNA expression profiles of multiple patients show alterations of genes involved with calcium signaling. Neurobiol Dis. 2006;21(3):618-625.

[2] Diaz JC, Simakova O, Jacobson KA, et al. Small molecule blockers of the Alzheimer Abeta calcium channel potently protect neurons from Abeta cytotoxicity. Proc Natl Acad Sci U S A. 2009;106(33):13488-13503.

[3] Demuro A, Parker I, Stutzmann GE. Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem. 2010;285(17):12463-12468.

[4] Kawahara M, Kuroda Y. Molecular mechanism of neurodegeneration induced by the beta-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res Bull. 2000;53(4):389-397.

[5] Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008;31(9):454-463.

[6] Chan CS, Guzman JN, Ilici E, et al. Rejuvenation protects neurons in mouse models of Parkinson's disease. Nature. 2007;447:1081-1086.

[7] Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem. 2009;110:1129-1134.

[8] Aneekonda TS, Quinl JP, Harris C, et al. L-type voltage-gated calcium channel blockade with irsadinpe as a therapeutic strategy for Alzheimer's disease. Neurobiol Dis. 2011;41:62-70.

[9] Zhang GR, Cheng XR, Zhou WX, et al. Age-related expression of calcium/calmodulin-dependent protein kinase II A in the hippocampus and cerebral cortex of senescence accelerated mouse prone/8 mice is modulated by anti-Alzheimer's disease drugs. Neuroscience. 2009;159(1):308-315.

[10] Kellner M, Fastbom J, Cowburn RF, et al. Alterations in the ryodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillar and beta-amyloid pathologies. Neuroscienc. 1999;92(2):499-513.

[11] Souid S, Lepesant JA, Yanicostas C. The xbp-1 gene is essential for development in Drosophila. Dev Genes Evol. 2007;217(2):159-167.

[12] Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med. 2008;14:45-53.

[13] Zhu X, Perry G, Moreira PI, et al. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J Alzheimers Dis. 2006;9(2):147-153.

[14] Wells RC, Picton LK, Williams SC, et al. Direct binding of the dynamin-like GTPase Dnm1 to mitochondrial dynamics protein Fis1 is negatively regulated by the Fis1 N-terminal arm. J Biol Chem. 2007;282:33769-33775.

[15] Knott AB, Perkins G, Schwarzenbacher R, et al. Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci. 2008;9:505-518.

[16] Song ZY, Ghochani M, McCaffery JM, et al. Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. Mol Biol Cell. 2009;20:3525-3532.

[17] Meuer K, Suppanz IE, Lingor P, et al. Cyclin-dependent kinase 5 is an upstream regulator of mitochondrial fission during neuronal apoptosis. Cell Death Differ. 2007;14:651-661.

[18] Cho DH, Nakamura T, Fang J, et al. S-nitrosylation of Drp1 mediates betaamyloid-related mitochondrial fission and neuronal injury. Science. 2009;324:102-105.

[19] Lee S, Jeong SY, Lim WC, et al. Mitochondrial fusion and fission mediators, Hf1 and OPA1, modulate cellular senescence. J Biol Chem. 2007;282:22977-22983.

[20] Wang X, Su B, Lee HG, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci. 2009;29:9090-9103.

[21] Wang X, Su B, Fujioha K, et al. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. Am J Pathol. 2008;173:470-482.

[22] Wang X, Su B, Siedlik SL, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A. 2008;105:19318-19323.

[23] Igual K, Grundke-Iqbal I. Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci. 2007;64:2234-2244.

[24] Dijkstra R, Ross JL, Goldman YE, et al. Differential regulation of dynnein and kinesin motor proteins by tau. Science. 2008;319:1086-1089.

[25] Areia-Gomez E, De Groof A, Boldogh I, et al. Prosenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am J Pathol. 2009;175:1810-1816.

[26] Quintanilla RA, Matthews-Roberson TA, Dolan PJ, et al. Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. J Biol Chem. 2009;284:18754-18766.

[27] Matthews-Roberson TA, Quintanilla RA, Ding H, et al. Immortalized cortical neurons expressing caspase-cleaved tau are sensitive to endoplasmic reticulum stress induced cell death. Brain Res. 2008;1234:206-212.

[28] Gura T. Hope in Alzheimer's right emerges from unexpected places. Nat Med. 2008;14:894.

[29] Reddy PH. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol. 2009;218:286-292.

[30] Brooks C, Wei Q, Cho SG, et al. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest. 2009;119:1275-1286.

[31] Wareski P, Vaarmann A, Choubyev Y, et al. PGC-1(alpha) and PGC-1(beta) regulate mitochondrial density in neurons. J Biol Chem. 2009;284:21379-21385.

[32] Qin W, Haroutunian V, Katsel P, et al. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol. 2009;66:352-361.

[33] Choudhary MI, Nawaz SA, Zaheer-ul-Haq, et al. Juliflorine: a potent natural peripheral anionic site-binding inhibitor of acetylcholinesterase with calcium-channel blocking potential, a leading candidate for Alzheimer's disease therapy. Biochem Biophys Res Commun. 2005;332(4):1171-1177.

[34] Deng H, Dodson MW, Huang H, et al. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci U S A. 2008;105:14503-14508.

[35] Grunevald A, Gegg ME, Taanman JW, et al. Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. Exp Neurol. 2009;219:266-273.

[36] Park J, Lee G, Chung J. The PINK1-Parkin pathway is involved in the regulation of mitochondrial remodeling process. Biochem Biophys Res Commun. 2009;378:518-523.

[37] Wang H, Lim PJ, Karbowski M, et al. Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum Mol Genet. 2009;18:737-752.

[38] Orr AL, Li S, Wang CE, et al. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci. 2008;28:2783-2792.

[39] Gomez Lazaro M, Bonekamp NA, Galindo MF, et al. 6-Hydroxydopamine (6-OHDA) induces Drp1-dependent mitochondrial fragmentation in SH-SY5Y cells. Free Radic Biol Med. 2008;44:1960-1969.

[40] Yang Y, Ouyang Y, Yang L, et al. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci U S A. 2008;105:7070-7075.

(Edited by Ding XH, Lin XD/Qiu Y/Song LP)